We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
- Authors
Cloughesy, Timothy F.; Landolfi, Joseph; Hogan, Daniel J.; Bloomfield, Stephen; Carter, Bob; Chen, Clark C.; Elder, J. Bradley; Kalkanis, Steven N.; Kesari, Santosh; Lai, Albert; Lee, Ian Y.; Liau, Linda M.; Mikkelsen, Tom; Nghiemphu, Phioanh Leia; Piccioni, David; Walbert, Tobias; Chu, Alice; Das, Asha; Diago, Oscar R.; Gammon, Dawn
- Abstract
The article presents the results of the phase 1 study of Toca 511 (vocimagene amiretrorepvec) and 5-fluorocytosine (FC) for recurrent high-grade glioma. It states that treatment of Toca 511 resulted in viral transduction of tumor cells as demonstrated by detection of Toca 511 DNA and expression of Toca 511 RNA and cytosine deaminase (CD) protein. It mentions that the median duration of treatment with Toca FC was two cycles.
- Subjects
GLIOMA treatment; CANCER cells; RNA analysis; CYTOSINE deaminase; CANCER treatment
- Publication
Science Translational Medicine, 2016, Vol 8, Issue 341, p1
- ISSN
1946-6234
- Publication type
Article
- DOI
10.1126/scitranslmed.aad9784